Physician profile
Farah Malik
NPI 1871523894
$3,671.24
in general payments reported to CMS, 2019-2025
30 companies · $649 in 2025
The $649 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $236 · 2021: $469 · 2022: $323 · 2023: $765 · 2024: $982 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,396.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $601.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $503.71 | 2021-2025 | |
| Lilly USA, LLC | $418.16 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $363.85 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $228.91 | 2020-2025 | Shingrix, Arexvy, Bexsero |
| Astellas Pharma US INC | $215.75 | 2023-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $213.04 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $201.96 | 2022-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Amgen INC. | $134.79 | 2019-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.47 | 2019-2024 | Jardiance, Synjardy |
| Exact Sciences Corporation | $114.30 | 2023-2025 | Cologuard Collection Kit |
| Bard Peripheral Vascular, INC. | $105.48 | 2021 | |
| Novartis Pharmaceuticals Corporation | $61.69 | 2022-2025 | |
| Amarin Pharma, INC. | $54.42 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $40.59 | 2022-2023 | Quviviq |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $40.42 | 2022-2025 | Bd Onclarity |
| Teva Pharmaceuticals USA, INC. | $34.73 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.99 | 2023 | Trintellix |
| Sanofi-Aventis U.S. LLC | $29.23 | 2019-2022 | |
| Allergan, INC. | $24.79 | 2020 | |
| Genentech USA, INC. | $24.14 | 2020 | |
| Aytu Biopharma, INC. | $18.40 | 2019 | |
| Ethicon US, LLC | $15.44 | 2019 | |
| Endo Pharmaceuticals INC. | $14.72 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.60 | 2022 | |
| Upsher-Smith Laboratories LLC | $13.42 | 2021 | |
| Hologic Sales and Service, LLC | $13.37 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.72 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farah Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.